AstraZeneca, Neurimmune Sign Exclusive Collaboration and License Agreement for NI006
07 Janeiro 2022 - 4:44AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Friday that it has signed an exclusive
global collaboration and license agreement with Neurimmune for the
development and commercialization of NI006, a treatment for
transthyretin amyloid cardiomyopathy.
The pharmaceutical giant said its rare disease group Alexion
will pay Neurimmune an upfront payment of $30 million, with the
potential for additional milestone payments of up to $730 million
based on development, regulatory and commercial milestones. In
addition, further low-to-mid teen royalties will be paid on net
sales of any approved medicine resulting from the agreement.
Under the deal, Alexion will be granted an exclusive worldwide
license to develop, manufacture and commercialize NI006.
NI006 is designed to treat transthyretin amyloid cardiomyopathy
by enabling the removal of amyloid fibril deposits in the heart,
with the potential to treat patients with advanced stages of the
condition.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
January 07, 2022 02:29 ET (07:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024